Лечение сосудистой коморбидности при ишемической болезни сердца и хронической ишемии мозга (обзор литературы)
DOI:
https://doi.org/10.31082/1728-452X-2021-224-2-35-42Ключевые слова:
ишемическая болезнь сердца, хроническая ишемия мозга, мексидолАннотация
Цель исследования. Обзор имеющихся исследований по применению эффективности и безопасности мексидола в лечении сосудистой коморбидности: при ишемической болезни сердца и хронической ишемии мозга.
Материал и методы. Обзор литературы по данным исследованиям был проведен с использованием поисковой системы eLIBRARY.RU за последние 5 лет, то есть с 2016 по 2020 годы
включительно.
Результаты и обсуждение. С включением ключевого слова «мексидол» за последние 5 лет найдено 396 публикаций, из них отобрано по теме данного обзора 40. В статье приведен обзор литературы и показана вазопротективная и геропротективная эффективность мексидола в лечении сосудистой коморбидности у пациентов старших возрастных групп с ИБС и хронической ишемией мозга. Мексидол оказывает влияние на ключевые, базисные процессы в клеточных структурах органов и тканей организма, возникающие при гипоксических состояниях, в том числе у пациентов с COVID-19.
Выводы. Представленные в настоящем обзоре данные свидетельствуют о результатах
исследований, которые доказывают, что мексидол, благодаря мультимодальному механизму действия, широкому спектру фармакологических эффектов, выраженному прямому антиоксидантному действию и высокому профилю безопасности, полностью отвечает принципам фармакологии препаратов, назначаемых пациентам старших возрастных групп, и является перспективным препаратом для терапии геронтологических больных, в особенности с сосудистой цереброкардиальной коморбидностью, а также у пациентов с COVID-19.
Библиографические ссылки
Serdechno-sosudistye zabolevaniia [Elektronnyi resurs]. Vsemirnaia Organizatsiia Zdravookhraneniia. [Cardiovascular diseases [Electronic resource]. World Health Organization]. Available from: https://www.who.int/ru/news-room/factsheets/detail/cardiovascular-diseases-(cvds)/
ICD-11 for Mortality and Morbidity Statistics (ICD-11 MMS) 2018 version, 04.2019 г. World Health Organization. Available from: https://icd.who. int/browse11/l-m/en
2016 European guidelines on cardiovascular disease prevention in clinical practice. Rossiiskii kardiologicheskii zhurnal = Russ J Cardiol. 2017;6(146):7–85. (In Russ.) http://dx.doi.org/10.15829/1560-4071-2017-6-7-85
Weber VR, Maydyrov ES, Karibaev KR. Age, gender and ethnic characteristics of coronary artery lesions in patients with coronary heart disease in Kazakhstan. Vestnik Novgorodskogo gosudarstvennogo universiteta = Bulletin of the Novgorod State University. 2020;1(117):118-121 (In Russ.)
Kirova YuI, Shakova FM, Germanova EL, Romanova GA, Voronina TA. The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. = 2020;120(1):62-69. (In Russ.). https://doi.org/10.17116/jnevro202012001162.
Wille M, Schumann A, Kreutzer M, Glocker MO, Wree A, et al. Differential Proteomics of the Cerebral Cortex of Juvenile, Adult and Aged Rats: An Ontogenetic Study. J Proteomics Bioinform. 2017;10:41-59. doi: 10.4172/jpb.1000424
Akhmetzhanova ZB, Medukhanova SG, Zhumabayeva GK, Adilbekov YB. Stroke in Kazakhstan. Zhurnal neirokhirurgiia i nevrologiia Kazakhstana = Journal of Neurosurgery and Neurology of Kazakhstan. 2019;2(50):8-21 (In Russ.)
Shchepankevich LA, Tanashyan MM, Nikolaev YuA, Polyakov VYa, Pervuninskaya MA, Antonova KV. Role of antioxidants in treatment and prevention of patients with high risk of cardiovascular complications. Kardiologiya i serdechno-sosudistaya khirurgiya = Cardiology and Cardiovascular Surgery. 2018;11(4):31-35. (In Russ.). https://doi.org/10.17116/kardio201811431
Sagynbaeva GA, Kaliev RR. Effectiveness of N-acetylcysteine and мexidol in the prevention of contrast-induced nephropathy in patients with coronary heart disease. Nauka, novye tekhnologii i innovatsii Kyrgyzstana = Science, New Technologies and Innovations in Kyrgyzstan. 2020;8:26-33. doi: 10.26104/NNTIK.2019.45.557
Eliseeva LN, Kartashova SV. Mexidol® and Mexidol® FORTE 250 in consecutive therapy of cognitive disorders in comorbid patients with joint pathology on the background of arterial hypertension and ischemic heart disease. Terapiia = Therapy. 2020; 6: 202–211. (In Russ.) doi: https://dx.doi.org/10.18565/therapy.2020.6.202–211
Oganov RG, Denisov IN, Simanenkov VI, Bakulin IG, et al. Comorbidities in practice. clinical guidelines. Kardiovaskuliarnaia terapiia i profilaktika = Cardiovascular Therapy and Prevention. 2017;16(6):5-56. (In Russ.) https://doi.org/10.15829/1728-8800-2017-6-5-56
Tsiryatieva SB, Pilenko SA, Arutyunan LA, Prichodko VV. Comorbidity Charlson index and metabolic dysfunction in patient with cardiac ischemia. Meditsinskaia nauka i obrazovanie Urala = Medical science and education in the Urals. 2017; 4(92): 162-165 (In Russ.)
Kovalyova ON. Semantic analysis and clinical importance of comorbidity and multimorbidity. Ukrainskii terapevticheskii zhurnal = Ukrainian Therapeutic Journal. 2019;2:79-86. (In Russ.) doi: http://doi.org/10.30978/UTJ2019-2-79
Gromova OA, Torshin IYu, Fedotova LE. Geriatric information analysis of the molecular properties of мexidolе. Nevrologiia, neiropsikhiatriia, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(4):46-54. (In Russ.) https://doi.org/10.14412/2074-2711-2017-4-46-54
Folch J, Busquets O, Ettcheto M, Sánchez-López E, Pallàs M, Beas-Zarate C, Marin M, Casadesus G, Olloquequi J, Auladell C, Camins A. Experimental Models for Aging and their Potential for Novel Drug Discovery. Curr Neuropharmacol. 2018;16(10):1466-1483. doi: 10.2174/1570159X15666170707155345. PMID: 28685671; PMCID: PMC6295931
Voronina TA. Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental study. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova = SS Korsakov Journal of Neurology and Psychiatry. 2020;120(4):81-87. https://doi.org/10.17116/jnevro202012004181 (In Russ.)
Voronina TA, Ivanova EA. Combined administration of mexidol with known medicines. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = SS Korsakov Journal of Neurology and Psychiatry = 2019;119(4):115-124. (In Russ.). https://doi.org/10.17116/jnevro2019119041115
Martemianova EG. Clinical aspects of ethylmethylhydroxypyridine succinate in elderly patients with cardiovascular pathology. Kardiovaskuliarnaia terapiia i profilaktika = Cardiovascular Therapy and Prevention. 2018;17(2):57–62. (In Russ.). http://dx.doi.org/10.15829/1728-8800-2018-2-57-62
Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of mexidol. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova = SS Korsakov Journal of Neurology and Psychiatry. 2018;118(12-2):87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
Shchulkin AV, Kazakhmedov ER, Galochkin SA, Tolkacheva VV, Kobalava ZhD. Effects of мexidol in patients with chronic brain ischemia and chronic heart failure (II-III functional class). Russ. Jour. of Card. and Cardiovasc. Surg. = Kard. i serd.-sosud. khir. 2020;13(5):427-434. (In Russ.). https://doi.org/10.17116/kardio202013051427
Garmonova OA, Zyazina VO, Kuznetsov SI. New in metabolic therapy of arrhythmic syndrome in patients with postinfarction cardiosclerosis. Sovremennaia nauka: aktualnye problemy teorii i praktiki. Seriia: Estestvennye i tekhnicheskie nauki = Modern Science: actual problems of theory and practice. Series of «Natural and technical sciences». 2019;5:128-133 (In Russ.)
Zolotovskaya IA, Duplyakov DV. Conceptual aspects of arterial hypertension treatment. Kardiologiya: novosti, mneniya, obuchenie = Cardiology: News, Opinions, Training. 2019;7(4):36–43. (in Russ.). doi: 10.24411/2309-1908-2019-14005
Kutashov VA, Ulyanova OV. The study of the efficacy and safety of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im SS Korsakova = SS Korsakov Journal of Neurology and Psychiatry. 2019;119(12 vyp 2):89-92. (In Russ.). https://doi.org/10.17116/jnevro201911912289
Semikasheva OV, Yakupova LR, Borisov IM, Safiullin RL. Quantitative analysis of the antioxidant activity of the medicine Mexidol. Khimiko-farmatsevticheskii zhurnal = Chemical and Pharmaceutical Journal. 2020;54(12):52-55. (In Russ.). doi: https://doi.org/10.30906/0023-1134-2020-54-12-52-55
Torshin IYu, Gromova OA, Sardaryan IS, Fedotova LE. Comparative chemoreactome analysis of Mexidol. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova = SS Korsakov Journal of Neurology and Psychiatry. 2017;117(1-2):75-83. (In Russ.). doi. 10.17116/jnevro20171171275-84
Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta. 2016 May;1862(5):915-25. doi: 10.1016/j.bbadis.2016.01.015. Epub 2016 Jan 22. PMID: 26806700; PMCID: PMC4827373
Calabrese V, Giordano J, Signorile A, Laura Ontario M, Castorina S, De Pasquale C, Eckert G, Calabrese EJ. Major pathogenic mechanisms in vascular dementia: Roles of cellular stress response and hormesis in neuroprotection. J Neurosci Res. 2016 Dec;94(12):1588-1603. doi: 10.1002/jnr.23925. Epub 2016 Sep 23. PMID: 27662637
Kapasi A, Schneider JA. Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons. Biochim Biophys Acta. 2016 May;1862(5):878-86. doi: 10.1016/j.bbadis.2015.12.023. Epub 2016 Jan 5. PMID: 26769363
Roth W, Morgello S, Goldman J, Mohr JP, Elkind MS, Marshall RS, Gutierrez J. Histopathological Differences Between the Anterior and Posterior Brain Arteries as a Function of Aging. Stroke. 2017 Mar;48(3):638-644. doi: 10.1161/STROKEAHA.116.015630. Epub 2017 Feb 14. PMID: 28196941; PMCID: PMC5330785
Chukanova EI, Chukanova AS. Efficacy and safety of the drug Mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal Nevrologii i Psikhiatrii im SS Korsakova = SS Korsakov Journal of Neurology and Psychiatry. 2019;119(9):39-45. (In Russ.) https://doi.org/10.17116/jnevro201911909139
Zharkinbekova NA. Chronic cerebral ischemia: review of published works, pathogenetic approaches to therapy. Meditsina (Almaty) = Medicine (Almaty). 2020;3-4(213-214):64-73. (In Russ.). doi: 10.31082/1728-452X-2020-213-214-3-4-64-73
Abramenko YuV. The efficacy and safety of Mexidol and Mexidol Forte 250 in patients with chronic cerebral ischemia. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova = SS Korsakov Journal of Neurology and Psychiatry. 2020;120(3(2):60-65. (In Russ.). https://doi.org/10.17116/jnevro202012003260
Vertkin AL. Effective tissue antiischemic therapy of etiologically various vascular diseases of the brain. Kardiovaskuliarnaia terapiia i profilaktika = Cardiovascular Therapy and Prevention. 2016;15(2):69–78 (In Russ.). http://dx.doi.org/10.15829/1728-8800-2016-2-69-78
Inchina VI, Korobkov DM, Repina EA, et al. Evaluation of antioxidant medication influence on processes of lipid peroxidation and determination of activity of the system of antioxidant plasma energy in the experiment with the use of alloxan-induced diabetes in combination with hypercholesterinemia. Mezhdunarodnyi nauchno-issledovatelskii zhurnal = International Research Journal. 2017:05(59) Part 2:134-135. (In Russ.). doi: 10.23670/IRJ.2017.59.045
Goncharova NY, Ketova ES, Korchagina SA, Ivakhnenko DV. Pharmacological effects of the medicine Mexidol in the treatment of type 2 diabetes mellitus. Molodezhnyi innovatsionnyi vestnik = Youth Innovative Bulletin. 2019; 8(2):495-497 (In Russ.)
Gorshkov IP, Sidorkina YuV, Naumova NV. Experience with Mexidol in the treatment of patients with type 2 diabetes with diabetic polyneuropathy. Biulleten eksperimentalnoi biologii i meditsiny = Bulletin of Experimental Biology and Medicine. 2012;1:205-210. (In Russ.)
Voronina TA. Antioxidants/antihypoxants: the missing puzzle piece in effective pathogenetic therapy for COVID-19. Infektsionnye bolezni = Infectious diseases. 2020;18(2):97–102. (In Russ.). doi: 10.20953/1729-9225-2020-2-97-102
Makiev GG, Gurina AE, Gabolaeva NA. Influence of Mexidol on condition of pro- and antioxidant systems in experimental acute respiratory distress syndrome. Voprosy biologicheskoi, meditsinskoi i farmatsevticheskoi khimii = Problems of biological, medical and pharmaceutical chemistry. 2018;21(8):52-57. (In Russ.). doi: https://doi.org/10.29296/25877313-2018-08-08
Pereverzev AP, Romanovsky RR, Golovina OV. Potential pharmacological methods to delay aging. Terapiia = Therapy. 2021; 4: XX–XX. (In Russ.) Doi: https://dx.doi.org/10.18565/therapy.2021.4.XX-XX
Spasennikov BA, Spasennikova MG. Mexidol and Phenazepam: 30 years of experimental and clinical study. Vestnik mezhdunarodnogo Instituta upravleniia. = Bulletin of the International Institute of Management. 2016;5-6(141-142):0-81. (In Russ.)
Загрузки
Опубликован
Выпуск
Раздел
Лицензия
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
